Adriamycin cardiomyopathy: Pathophysiology and prevention

FASEB Journal

Volumn 11, Issue 12, 1997, Pages 931-936

  Singal, Pawan K ^a,b   Iliskovic, Natasha ^a   Li, Timao ^a   Kumar, Dinender ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b ST BONIFACE GENERAL HOSPITAL RESEARCH CENTRE   (Canada)

Author keywords

Antioxidants; Heart failure; Oxidative stress; Probucol

Indexed keywords

ANTIOXIDANT; DOXORUBICIN; PROBUCOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CARDIOMYOPATHY; CARDIOTOXICITY; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG SAFETY; HEART FAILURE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROMOTER REGION; RAT; REVIEW; ST SEGMENT DEPRESSION;

ANIMALIA;

EID: 0030855953     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fasebj.11.12.9337145     Document Type: Review

References (83)

1. Di Marco, A., Gaetani, M., and Scarpinato, B. (1969) Adriamycin (NSC-123, 127): A new antibiotic with antitumor activity. Cancer Chemother. Rep. 53, 33-37
2. Arcamone, F., Cassineli, G., Fantini, G., Grein, A., Orezzi, P., Pol, C., and Spalla, C. (1969) Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol. Bioengin. 9, 1101-1110
3. Lefrak, E. A., Pitha, J., Rosenheim, S., and Gottleib, J. A. (1973) A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32, 302-314
4. Gilladoga, A. C., Manuel, C., Tan, T. C., Wollver, N., Sternberg, S. S., and Murphy, M. L. (1976) The cardiotoxicity of adriamycin and daunomycin in children. Cancer 37, 1070-1078
5. Bristow, M. R., Thompson, P. D., Martin, R. P., Mason, J. W., Billingham, M. E., and Harrison, D. C. (1978) Early anthracycline cardiotoxicity. Am. J. Med. 65, 823-832
6. Von Hoff, D. D., Layard, M. W., Basa, P., Davis, H. L., Von Hoff, A. L., Rozencweig, M., and Muggia, F. M. (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann. Int. Med. 91, 710-717
7. Bonadonna, G., Monfardini, S., De Lena, M., Fassati-Bellani, F., and Beretta, G. (1970) Phase I and preliminary phase II evaluation of adriamycin (NSC 123127). Cancer Res. 30, 2572-2582
8. Minow, R. A., Benjamin, R. S., Lee, E. F., and Gottlieb, J. A. (1977) Adriamycin cardiomyopathy - risk factors. Cancer 39, 1397-1402
9. Steinhertz, L. J., Steinhertz, P. G., Tan, C. T. C., Heller, G., and Murphy, L. (1991) Cardiac toxicity 4 to 20 years after completing anthracycline therapy. J. Am. Med. Assoc. 266, 1672-1677
10. Shapira, J., Gotfried, M., Lishner, M., and Ravid, M. (1990) Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. Cancer 65, 870-873
11. Legha, S. S., Benjamin, R. S., Mackay, B., Ewer, M., Wallace, S., Valdivieso, M., Rasmussen, S., Blumenschein, G. R., and Freireich, E. J. (1982) Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann. Int. Med., 96, 133-139
12. Weiss, R. B. (1992) The anthracyclines: will we ever find a better doxorubicin? Semin. Oncol. 19, 670-686
13. Singal, P. K., Siveski-Iliskovic, N., Hill, M., Thomas, T. P., and Li, T. (1995) Combination therapy with probucol prevents adriamycin-induced cardiomyopathy. J. Mol. Cell. Cardiol. 27, 1055-1063
14. Siveski-Iliskovic, N., Kaul, N., and Singal, P. K. (1994) Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation 89, 2829-2835
15. Siveski-Iliskovic, N., Hill, M., Chow, D. A., and Singal, P. K. (1995) Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation 91, 10-15
16. Herman, E. H., Matre, R. M., Lee, I. P., Vick, J., and Warardekarv, V. S. (1971) A comparison of the cardiovascular actions of daunomycin, adriamycin and M-acetyl-daunomycin in hamsters and monkeys. Pharmacology 6, 230-241
17. Arena, E., D'Alessandro, N., Dusonchet, L., Gebbia, N., and Gerbasi, F. (1972) Influence of pharmacokinetic variations on the pharmacologic properties of adriamycin. In International Symposium on Adriamycin (Carter, S. K., DiMarco, A., Ghione, M., Krekoff, I. H., Mathe, G., eds) pp. 96-116, Springer-Verlag, New York
18. van Acker, S. A. B. E., Kramer, K., Voest, E. E., Grimbergen, J. A., Zhang, J., van der Vijgh, W. J. F., and Bast, A. (1996) Doxorubicin-induced cardiotoxicity monitored by ECG in freely moving mice. Cancer Chemother. Pharmacol. 38, 95-101
19. Buja, L. M., Ferrans, V. J., Mayer, R. J., Roberts, W. C., and Henderson, E. S. (1973) Cardiac ultrastructural changes induced by daunorubicin therapy. Cancer 32, 771-778
20. Bristow, M. R., Mason, J. W., Billingham, M. E., and Daniels, J. R. (1981) Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am. Heart J. 102, 709-718
21. Bristow, M. R. (1982) Toxic cardiomyopathy due to doxorubicin. Hosp. Pract. 17, 101-111
22. Jones, S. M., Kirby, M. S., Harding, S. E., Vescova, G., Wanless, R. B., Dalla-Libera, L. D., and Poole-Wilson, P. A. (1990) Adriamycin cardiomyopathy in the rabbit: Alterations in contractile proteins and myocyte function. Cardiovasc. Res. 24, 834-842
23. Tong, J., Ganguly, P. K., and Singal, P. K. (1991) Myocardial adrenergic changes at two stages of heart failure due to adriamycin treatment in rats. Am. J. Physiol. 260, H909-H916
24. Siveski-Iliskovic, N., Thomas, T. P., Kaul, N., Slezak, J., and Singal, P. K. (1994) Doxorubicin-induced cardiomyopathy: a model of congestive heart failure. In The Cardiomyopathic Heart (Nagano, M., Takeda, N., Dhalla, N, S., eds) pp. 277-283, Raven Press, New York
25. Chalcroft, S. C. W., Gavin, J. B., and Herdon, P. B. (1973) Fine structure changes in rat myocardium induced daunorubicin. Pathology 5, 99-105
26. Singal, P. K., Segstro, R. J., Singh, R. P., and Kutryk, M. J. (1985) Changes in lysosomal morphology and enzyme activities during the development of adriamycin-induced cardiomyopathy. Can. J. Cardiol. 1, 139-147
27. Arena, E., Biondo, R., D'Alessandro, N., Dusonchet, L., Gebbia, N., and Gerbasi, F. (1974) DNA, RNA and protein synthesis in heart liver and brain of mice treated with daunorubicin or adriamycin. Int. Res. Commun. Systemic Med. Sci. 2, 1053-1061
28. Monti, E., Prosperi, E., Supino, R., and Bottiroli, G. (1995) Free radical-dependent DNA lesions are involved in the delayed cardiotoxicity induced by adriamycin in the rat. Anticancer Res. 15, 193-197
29. Bristow, M. R., Sageman, W. S., Scott, R. H., Billingham, M.E., Bowden, R. E., Kernoff, R. S., Snidow, I. H., and Daniels, J. R. (1980) Acute and chronic cardiovascular effects of doxorubicin in the dog: The cardiovascular pharmacology of drug-induced histamine release. J. Cardiovasc. Pharmacol. 2, 487-515
30. Gosalvez, M., van Rossum, G. D. V., and Blanco, M. F. (1979) Inhibition of sodium-potassium activated adenosine 5′-triphosphatase and ion transport by adriamycin. Cancer Res. 39, 257-261
31. 2+ binding and lipid peroxidation but depresses myocardial function. Am. J. Physiol. 250, H419-H425
32. Singal, P. K., and Panagia, V. (1984) Direct effects of adriamycin on the rat heart sarcolemma. Res. Commun. Chem. Pathol. Pharmacol. 43, 67-77
33. Olson, H. M., Young, D. M., Prieur, D. J., LeToy, A. F., and Reagan, R. L. (1974) Electrolyte and morphologic alterations of myocardium in adriamycin-treated rabbits. Am. J. Pathol. 77, 439-454
34. Singal, P. K., Deally, C. M. R., and Weinberg, L. E. (1987) Subcellular effects of adriamycin in the heart: A concise review. J. Mol. Cell. Cardiol. 19, 817-828
35. Kalyanaraman, B., Perez-Reyes, E., and Mason, R. P. (1980) Spin-trapping and direct electron spin resonance investigations of the redox metabolism of quinone anticancer drugs. Biochem. Biophys. Acta 630, 119-130
36. Doroshow, J. H. (1983) Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res. 43, 460-472
37. Myers, C. E., McGuire, W. P., Liss, R. H., Ifrim, I., Grotzinger, K., and Young, R. C. (1977) Adriamycin: The role of lipid peroxidation in cardiac toxicity and tumor response. Science 197, 165-167
38. Doroshow, J. H., Locker, G. Y., Baldinger, J., and Myers, C. E. (1979) The effect of doxorubicin on hepatic and cardiac glutathione. Res. Commun. Chem. Pathol. Pharmacol. 26, 285-295
39. Olsen, R. D., MacDonald, T. S., and Vanboxtel, C. J. (1980) Regulatory role of glutathione and soluble sulfhydryl groups in the toxicity of adriamycin. J. Pharmacol. Exp. Ther. 215, 450-458
40. Odom, A. L., Hatwig, C. A., Stanley, J. S., and Benson, A. M. (1992) Biochemical determinants of adriamycin toxicity in mouse liver, heart and intestine. Biochem. Pharmacol. 43, 831-836
41. Thornalley, P. J., and Dodd, N. J. F. (1985) Free radical production from normal and adriamycin-treated rat cardiac sarcosomes. Biochem. Pharmacol. 34, 669-674
42. Costa, L., Malatests, V., Morazzoni, F., Scotti, R., Monti, E., and Paracchini, L. (1988) Direct detection of paramagnetic species in adriamycin perfused rat hearts. Biochem. Biophys. Res. Commun. 153, 275-280
43. Alegria, A. E., Samuni, A., Mitchell, J. B., Riesz, P., and Russo, A. (1989) Free radicals induced by adriamycin-sensitive and adriamycin-resistant cells: A spin-trapping study. Biochemistry 28, 8653-8658
44. Berlin, V., and Haseltine, W. A. (1981) Reduction of adriamycin to a semiquinone-free radical by NADPH cytochrome P-450 reductase produces DNA cleavage in a reaction mediated by molecular oxygen. J. Biol. Chem. 256, 4747-4756
45. Bachur, N. R., Gordon, S. L., Gee, M. V., and Kon, H. (1979) NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. Proc. Natl. Acad. Sci. USA 76, 954-957
46. Kaul, N., Siveski-Iliskovic, N., Hill, M., Slezak, J., and Singal, P. K. (1993) Free radicals and the heart. J. Pharmacol. Toxicol. Methods 30, 55-67
47. Bachur, N. R., Gee, M. V., and Friedman, R. D. (1982) Nuclear catalyzed antibiotic free radical foramtion. Cancer Res. 42, 1078-1081
48. Sinha, B. K., Katki, A. G., Batist, G., Cowan, K. H., and Myers, C. E. (1987) Adriamycin-stimulated hydroxyl radical formation in human breast tumor cells. Biochem. Pharmacol. 36, 793-796
49. Sinha, B. K., Katki, A. G., Batist, G., Cowan, K. H., and Myers, C. E. (1987) Differential formation of hydroxyl radicals by Adriaycin in sensitive and resistant MCF-7 human breast tumor cells: implications for the mechanism of action. Biochemistry 26, 3776-3781
50. Potmesil, M., Israel, M., and Silver, R. (1984) Two mechanisms of adriamycin-DNA interaction in L1210 cells. Biochem. Pharmacol. 33, 3137-3142
51. Panneerselvam, M., Bredehorst, R., and Vogel, C. W. (1987) Cell surface cytotoxic effect of immobilized doxorubicin is target cell-dependent and involves oxygen radical formation. Proc. Am. Ass. Cancer Res. 28, 267
52. Muindi, J. R. F., Sinha, B. K., Gianni, L., and Myers, C. E. (1984) Hydroxyl radical production and DNA damage induced by anthracycline-iron complex. FEBS Lett. 172, 226-230
53. Muindi, J., Sinha, B. K., Gianni, L., and Myers, C. (1985) Thiol-dependent DNA damage produced by anthracycline-iron complexes; the structure-activity relationships and molecular mechanisms. Mol. Pharmacol. 27, 356-365
54. Eliot, H., Gianni, L., and Myers, C. (1984) Oxidative destruction of DNA by the adriamycin-iron complex. Biochemistry 23, 928-936
55. Breen, A. P., and Murphy, J. A.. (1995) Reactions of oxyl radicals with DNA. Free Radical Biol. & Med. 18, 1033-1077
56. Singal, P. K., Siveski-Iliskovic, N., Li, T., and Seneviratne, C. (1995) Cardiomyopathie due á l'adriamycine et sa prévention. L'information Cardiologique 19, 289-302
57. Shimpo, K., Nagatsu, T., Yamada, K., Sato, T., Niimi, H., Shamoto, M., Takeuchi, T., Umezawa, H., and Fujita, K. (1991) Ascorbic acid and adriamycin toxicity. Am. J. Clin. Nutr. 54 (Suppl. 6), 1298S-1301S
58. Cervantes, A., Pinedo, H. M., Lankelma, J., and Schuurhuis, G. J. (1988) The role of oxygen-derived free radicals in the cytotoxicity of doxorubicin in multidrug resistant and sensitive human ovarian cancer cells. Cancer Lett. 41, 169-177
59. Myers, C. E., Bonow, R., Palmeri, S., Jenkins, J., Corden, G., Locker, G., Doroshow, J., and Epstein, S. A. (1983) A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin. Oncol. 10 (Suppl. 1), 53-55
60. Yoda, Y., Nakazawa, M., Abe, T., and Kawakami, Z. (1986) Prevention of doxorubicin myocardial toxicity in mice by reduced glutathione. Cancer Res. 46, 2551-2556
61. Sinha, B. K., and Chignell, C. F. (1979) Binding mode of chemically activated semiquinone free radicals from quinone anticancer agents to DNA. Chem. Biol. Interact. 28, 301-308
62. Graves, D. E., and Krugh, T. R. (1983) Adriamycin and daunorubicin bind in a cooperative manner to deoxyribonucleic acid. Biochemistry 22, 3941-3947
63. Holm, C. O., Stearns, T., and Botstein, D. (1989) DNA topoisomerase II must act at mitosis to prevent nondisjunction and chromosome breakage. Mol. Cell. Biol. 9, 159-168
64. Capranico, G., Tinelli, S., and Zunino, F. (1989) Formation, resealing and persistence of DNA breaks produced by 4-demethoxydaunorubicin in P388 leukemia cells. Chem. Biol. Interact. 72, 113-123
65. Deffie, A. M., Batra, J. K., and Goldenberg, G. J. (1989) Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res. 49, 58-62
66. Skladanowski, A., and Konopa, J. (1993) Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumor cells. Biochem. Pharmacol. 46, 375-382
67. Anand, S., Verma, H., Kumar, L., and Singh, N. (1995) Induction of apoptosis in chronic myelogenous leukemia lymphocytes by hydroxyurea and adriamycin. Cancer Lett. 88, 101-105
68. Cece, R., Cazzaniga, S., Morelli, D., Sfondrini, L., Bignotto, M., Ménard, S., Colnaghi, M. I., and Balsari, A. (1996) Apoptosis of hair follicle cells during doxorubicin-induced alopecia in rats. Lab. Invest. 75, 601-609
69. Zhang, J., Clark, J. R., Jr., Herman, E.H., and Ferrans, V.J. (1996) Doxorubicin-induced apoptosis in spontaneously hypertensive rats: differential effects in heart, kidney and intestine, and inhibition by ICRF-187. J. Mol. Cell. Cardiol. 28, 1931-1943
70. Mimnaugh, E. G., Siddik, Z. H., Drew, R., Sikic, B. I., and Gram, T. E. (1979) The effects of α-tocopherol on the toxicity, disposition and metabolism of adriamycin in mice. Toxicol. Appl. Pharmacol. 49, 119-126
71. Hermansen, K., and Wassermann, K. (1986) The effects of vitamin E and selenium on doxorubicin (adriamycin) induced delayed toxicity in mice. Acta Pharmacol. Toxicol. 58, 31-37
72. Van Vleet, J. F., Ferrans, V. J., and Weirich, W. E. (1980) Cardiac disease induced by chronic adriamycin administration in dogs and evaluation of vitamin E and selenium as cardioprotectants. Am. J. Pathol. 99, 13-42
73. Pritsos, C. A., Sokoloff, M., and Gustafson, D. L. (1992) PZ-51 (Ebseliu) in vivo protection against adriamycin-induced mouse cardiac and hepatic lipid peroxidation and toxicity. Biochem. Pharmacol. 44, 839-841
74. Balanehru, S., and Nagarajan, B. (1992) Intervention of adriamycin-induced free radical damage. Biochem. Int. 28, 735-744
75. Nowak, D., Pierscinski, G., and Drzewoski, J. (1995) Ambroxol inhibits doxorubicin-induced lipid peroxidation in heart of mice. Free Radical Biol. & Med. 19, 659-663
76. Kang, Y. J., Chen, Y., and Epstein, P. N. (1996) Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice. J. Biol. Chem. 271, 12610-12616
77. 3+ reduction, lipid peroxidation, and CaATPase inactivation in heart microsomes exposed to adriamycin. Cancer Res. 50, 2307-2310
78. Seifert, C. F., Nesser, M. E., and Thompson, D. F. (1994) Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity. Ann. Pharmacother. 28, 1063-1072
79. Herman, E. H., and Ferrans, V. J. (1981) Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (I) - 1, 2-Bis (3,5-dioxopiperozinyl-1-yl) propane (ICRF-187). Cancer Res. 41, 3436-3440
80. Von Hoff, D. D., Howser, D., Lewis, B. J., Holcenberg, J., Weiss, R. B., and Young, R. C. (1981) Phase I study of ICRF-187 using a daily for 3 days schedule. Cancer Treat. Rep. 65, 249-252
81. Pryor, W. A., Strickland, T., and Church, D. F. (1988) Comparison of the efficiencies of several natural and synthetic antioxidants in aqueous sodium dodecyl sulfate micelle solutions. J. Am. Chem. Soc. 110, 2224-2229
82. Mao, S. J. T., Yates, M. T., Rechtin, A. E., Jackson, R. L., and van Sickle, W. A. (1991) Antioxidant activity of probucol and its analogues in hypercholesterolemic Watanabe rabbits. J. Med. Chem. 34, 298-302
83. Iliskovic, N., and Singal, P. K. (1997) Lipid-lowering: An important factor in preventing adriamycin-induced heart failure. Am. J. Pathol. 150, 727-734